AdaptHealth sells off infusion assets Company uses proceeds to make prepayment on outstanding term loan
By HME News Staff
Updated 7:58 AM CDT, Tue July 1, 2025
CONSHOHOCKEN, Pa. – AdaptHealth has completed the sale of certain infusion assets in its Wellness at Home segment to a third party.
The move was previously disclosed and the transaction was completed in June.
“The disposition of certain infusion assets marks yet another significant step in our effort to sharpen our strategic focus by exiting ancillary product lines,” said Suzanne Foster, CEO. “Additionally, the sale advances our commitment to debt reduction to unlock value for our shareholders.”
The company used the proceeds of the sale, and other funds, to make a prepayment of $65 million on its outstanding term loan. This prepayment was in addition to a previously announced $70 million prepayment on the term loan in May, funded primarily with proceeds from the sale of certain incontinence assets.
The products included in the sale of certain infusion assets represented approximately $52 million of annual revenue and approximately $5 million of annual adjusted EBITDA. Additionally, the AdaptHealth projects $30 million of cash taxes due on the gains from this sale.
To reflect these impacts, AdaptHealth is revising its full-year revenue guidance to a range of $3,150 million to $3,290 million, its full-year 2025 adjusted EBITDA to a range of $662 million to $702 million, and its full-year 2025 free cash flow to a range of $170 million to $190 million.
Comments